公开(公告)号：WO2017075124A1

公开(公告)日：2017-05-04

申请号：PCT/US2016/058975

申请日：2016-10-27

Applicant: MERCK SHARP & DOHME CORP. ,  VORA, Kalpit, A. ,  COX, Kara, S. ,  TANG, Aimin ,  CHEN, Zhifeng ,  DISTEFANO, Daniel ,  ZHANG, Lan ,  SU, Hua-Poo

Inventor： VORA, Kalpit, A. ,  COX, Kara, S. ,  TANG, Aimin ,  CHEN, Zhifeng ,  DISTEFANO, Daniel ,  ZHANG, Lan ,  SU, Hua-Poo

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1027 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Abstract translation: 本发明涉及具有高抗RSV中和滴度的单克隆抗体。 本发明进一步提供了编码本发明抗体的分离的核酸和用其转化的宿主细胞。 本发明进一步提供了采用本发明的抗体和核酸的诊断，预防和治疗方法，特别是作为婴幼儿和老年人的被动免疫治疗剂。

公开(公告)号：WO2022173714A2

公开(公告)日：2022-08-18

申请号：PCT/US2022/015565

申请日：2022-02-08

Applicant: MERCK SHARP & DOHME LLC ,  CHEN, Zhifeng ,  COX, Kara, S. ,  FRIDMAN, Arthur ,  GALLI, Jennifer Dawn ,  SU, Hua-Poo ,  TANG, Aimin ,  VORA, Kalpit ,  WEN, Zhiyun ,  XIAO, Xiao ,  ZHANG, Lan

Inventor： CHEN, Zhifeng ,  COX, Kara, S. ,  FRIDMAN, Arthur ,  GALLI, Jennifer Dawn ,  SU, Hua-Poo ,  TANG, Aimin ,  VORA, Kalpit ,  WEN, Zhiyun ,  XIAO, Xiao ,  ZHANG, Lan

IPC: A61K39/395 ,  C07K16/1018 ,  C07K16/1027 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to anti-human metapneumovirus (hMPV) antibodies, as well as use of such antibodies in the treatment of viral infections. The invention also includes antigenic hMPV proteins and immunogenic compositions comprising such antigenic hMPV proteins, and the use of such antigenic hMPV proteins and related compositions for preventing or treating viral infection in a subject.